Drugs / Herceptin Hylecta®
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | HERCEPTIN HYLECTA | — | 2024-06-18 | fda.gov ↗ |
| Approved | US (FDA) | HERCEPTIN HYLECTA | — | 2019-02-28 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07299955 | Feb → Jun 2026 overdue | — | Biocon Biologics UK Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Herceptin Hylecta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07299955 ↗ |
| Route | Subcutaneous | “single subcutaneous injection” NCT07299955 ↗ |